|Slideshows|August 3, 2020

Key Concepts About Polypharmacy in Psychotic Disorders

Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

schizophrenia cobenfy data analysis inpatient

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

ByJessica Walters

November 14th 2025

iclepertin cognitive impairment schizophrenia

Iclepertin Found Ineffective in Treating Cognitive Impairment Associated With Schizophrenia

ByJessica Walters

November 13th 2025

Placebo Response Rates Vary Across Psychiatric Disorders

ByMasha Impallaria, MD,Ahmed Sakr, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 12th 2025

Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia Severity

ByJessica Walters

November 12th 2025

Let’s Retire Haloperidol

ByJohn J. Miller, MD

November 11th 2025

Latest CME

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Key Concepts About Polypharmacy in Psychotic Disorders

Newsletter

Related Content

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

Iclepertin Found Ineffective in Treating Cognitive Impairment Associated With Schizophrenia

Placebo Response Rates Vary Across Psychiatric Disorders

Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia Severity

Let’s Retire Haloperidol

Latest CME

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Lamotrigine: An Update on Its Role in Bipolar Disorder

In Memoriam: 2 Terrible Ironies of Being a Psychiatrist

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

“Futures Thinking”: How to Think About the Future, Part 1